0 0 0
This online shop is using cookies to give you the best shopping experience. Thereby for example the session information or language setting are stored on your computer. Without cookies the range of the online shop's functionality is limited. If you don't agree, please click here.
Overview
Product 470 of 1070
Biologic and Systemic Agents in Dermatology

Yamauchi Biologic and Systemic Agents in Dermatology

ISBN: 978-3-319-66883-3

Edition: 1st Ed.

Publication date: January 2018

Cover: Hardcover

Pages: 574 p.

Illustrations: 94 ill.

Publisher: Springer

Delivery times, dependent on availability and publisher: between 2 and 14 days from when you complete the order.

Description

  • Written by leading experts in the field for dermatologists and dermatology residents
  • Describes the mechanism of action of various systemic and biologic agents, as well as their clinical efficacy and safety
  • Includes evidence-based medicine that underscores clinical data
  • Includes practical tips on how to use these agents
  • Topics covered include tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis
Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders, including psoriasis and atopic dermatitis, as well as skin malignancies such as melanoma.

Biologic and Systemic Agents in Dermatology encompasses these developments by describing the mechanism of action of these various agents and the clinical efficacy and safety to treating these respective disorders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis.